CovidChloroV1, Main, Curation, bibRecord, 001A01

Drug repositioning is an alternative for the treatment of coronavirus COVID-19.

Identifieur interne : 001A01 ( Main/Curation ); précédent : 001A00; suivant : 001A02

Drug repositioning is an alternative for the treatment of coronavirus COVID-19.

Auteurs : Marissa B. Serafin [Brésil] ; Angelita Bottega [Brésil] ; Vit Ria S. Foletto [Brésil] ; Taciéli F. Da Rosa [Brésil] ; Andreas Hörner ; Rosmari Hörner [Brésil]

Source :

International journal of antimicrobial agents [ 1872-7913 ] ; 2020.

RBID : pubmed:32278811

Descripteurs français

KwdFr :
- AMP (analogues et dérivés), AMP (usage thérapeutique), Alanine (analogues et dérivés), Alanine (usage thérapeutique), Antiviraux (usage thérapeutique), Betacoronavirus (effets des médicaments et des substances chimiques), Chloroquine (usage thérapeutique), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Infections à coronavirus (traitement médicamenteux), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Repositionnement des médicaments (méthodes), Téicoplanine (usage thérapeutique).
MESH :
- analogues et dérivés : AMP, Alanine.
- effets des médicaments et des substances chimiques : Betacoronavirus.
- méthodes : Repositionnement des médicaments.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : AMP, Alanine, Antiviraux, Chloroquine, Hydroxychloroquine, Téicoplanine.
- Humains, Pandémies.

English descriptors

KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (therapeutic use), Alanine (analogs & derivatives), Alanine (therapeutic use), Antiviral Agents (therapeutic use), Betacoronavirus (drug effects), COVID-19 (MeSH), Chloroquine (therapeutic use), Coronavirus Infections (drug therapy), Drug Repositioning (methods), Humans (MeSH), Hydroxychloroquine (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH), Teicoplanin (therapeutic use).
MESH :
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , therapeutic use : Adenosine Monophosphate, Alanine, Antiviral Agents, Chloroquine, Hydroxychloroquine, Teicoplanin.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- methods : Drug Repositioning.
- COVID-19, Humans, Pandemics, SARS-CoV-2.

Abstract

Given the extreme importance of the current pandemic caused by COVID-19, and as scientists agree there is no identified pharmacological treatment, where possible, therapeutic alternatives are raised through drug repositioning. This paper presents a selection of studies involving drugs from different pharmaceutical classes with activity against SARS-CoV-2 and SARS-CoV, with the potential for use in the treatment of COVID-19 disease.

DOI: 10.1016/j.ijantimicag.2020.105969
PubMed: 32278811
PubMed Central: PMC7194941

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A01

Links to Exploration step

pubmed:32278811

Curation

No country items

Andreas Hörner

<affiliation><nlm:affiliation>Universidade Federal de Santa Maria, Pós-Graduação Mestrado Profissional em Ciências da Saúde.</nlm:affiliation>
<wicri:noCountry code="subField">Pós-Graduação Mestrado Profissional em Ciências da Saúde</wicri:noCountry>
</affiliation>

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drug repositioning is an alternative for the treatment of coronavirus COVID-19.</title>
<author><name sortKey="Serafin, Marissa B" sort="Serafin, Marissa B" uniqKey="Serafin M" first="Marissa B" last="Serafin">Marissa B. Serafin</name>
<affiliation wicri:level="1"><nlm:affiliation>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bottega, Angelita" sort="Bottega, Angelita" uniqKey="Bottega A" first="Angelita" last="Bottega">Angelita Bottega</name>
<affiliation wicri:level="1"><nlm:affiliation>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Foletto, Vit Ria S" sort="Foletto, Vit Ria S" uniqKey="Foletto V" first="Vit Ria S" last="Foletto">Vit Ria S. Foletto</name>
<affiliation wicri:level="1"><nlm:affiliation>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Da Rosa, Tacieli F" sort="Da Rosa, Tacieli F" uniqKey="Da Rosa T" first="Taciéli F" last="Da Rosa">Taciéli F. Da Rosa</name>
<affiliation wicri:level="1"><nlm:affiliation>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Horner, Andreas" sort="Horner, Andreas" uniqKey="Horner A" first="Andreas" last="Hörner">Andreas Hörner</name>
<affiliation><nlm:affiliation>Universidade Federal de Santa Maria, Pós-Graduação Mestrado Profissional em Ciências da Saúde.</nlm:affiliation>
<wicri:noCountry code="subField">Pós-Graduação Mestrado Profissional em Ciências da Saúde</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Horner, Rosmari" sort="Horner, Rosmari" uniqKey="Horner R" first="Rosmari" last="Hörner">Rosmari Hörner</name>
<affiliation wicri:level="1"><nlm:affiliation>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil; Universidade Federal de Santa Maria, Departamento de Análises Clínicas e Toxicológicas, Santa Maria, RS, Brasil. Electronic address: rosmari.ufsm@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil; Universidade Federal de Santa Maria, Departamento de Análises Clínicas e Toxicológicas, Santa Maria, RS</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32278811</idno>
<idno type="pmid">32278811</idno>
<idno type="doi">10.1016/j.ijantimicag.2020.105969</idno>
<idno type="pmc">PMC7194941</idno>
<idno type="wicri:Area/Main/Corpus">001A01</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001A01</idno>
<idno type="wicri:Area/Main/Curation">001A01</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001A01</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Drug repositioning is an alternative for the treatment of coronavirus COVID-19.</title>
<author><name sortKey="Serafin, Marissa B" sort="Serafin, Marissa B" uniqKey="Serafin M" first="Marissa B" last="Serafin">Marissa B. Serafin</name>
<affiliation wicri:level="1"><nlm:affiliation>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bottega, Angelita" sort="Bottega, Angelita" uniqKey="Bottega A" first="Angelita" last="Bottega">Angelita Bottega</name>
<affiliation wicri:level="1"><nlm:affiliation>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Foletto, Vit Ria S" sort="Foletto, Vit Ria S" uniqKey="Foletto V" first="Vit Ria S" last="Foletto">Vit Ria S. Foletto</name>
<affiliation wicri:level="1"><nlm:affiliation>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Da Rosa, Tacieli F" sort="Da Rosa, Tacieli F" uniqKey="Da Rosa T" first="Taciéli F" last="Da Rosa">Taciéli F. Da Rosa</name>
<affiliation wicri:level="1"><nlm:affiliation>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Horner, Andreas" sort="Horner, Andreas" uniqKey="Horner A" first="Andreas" last="Hörner">Andreas Hörner</name>
<affiliation><nlm:affiliation>Universidade Federal de Santa Maria, Pós-Graduação Mestrado Profissional em Ciências da Saúde.</nlm:affiliation>
<wicri:noCountry code="subField">Pós-Graduação Mestrado Profissional em Ciências da Saúde</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Horner, Rosmari" sort="Horner, Rosmari" uniqKey="Horner R" first="Rosmari" last="Hörner">Rosmari Hörner</name>
<affiliation wicri:level="1"><nlm:affiliation>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil; Universidade Federal de Santa Maria, Departamento de Análises Clínicas e Toxicológicas, Santa Maria, RS, Brasil. Electronic address: rosmari.ufsm@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil; Universidade Federal de Santa Maria, Departamento de Análises Clínicas e Toxicológicas, Santa Maria, RS</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">International journal of antimicrobial agents</title>
<idno type="eISSN">1872-7913</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term>
<term>Adenosine Monophosphate (therapeutic use)</term>
<term>Alanine (analogs & derivatives)</term>
<term>Alanine (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (drug effects)</term>
<term>COVID-19 (MeSH)</term>
<term>Chloroquine (therapeutic use)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Drug Repositioning (methods)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Teicoplanin (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>AMP (analogues et dérivés)</term>
<term>AMP (usage thérapeutique)</term>
<term>Alanine (analogues et dérivés)</term>
<term>Alanine (usage thérapeutique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Betacoronavirus (effets des médicaments et des substances chimiques)</term>
<term>Chloroquine (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Repositionnement des médicaments (méthodes)</term>
<term>Téicoplanine (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
<term>Antiviral Agents</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
<term>Teicoplanin</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Repositioning</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Repositionnement des médicaments</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
<term>Antiviraux</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
<term>Téicoplanine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Pandémies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Given the extreme importance of the current pandemic caused by COVID-19, and as scientists agree there is no identified pharmacological treatment, where possible, therapeutic alternatives are raised through drug repositioning. This paper presents a selection of studies involving drugs from different pharmaceutical classes with activity against SARS-CoV-2 and SARS-CoV, with the potential for use in the treatment of COVID-19 disease.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32278811</PMID>
<DateCompleted><Year>2020</Year>
<Month>06</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7913</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>55</Volume>
<Issue>6</Issue>
<PubDate><Year>2020</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>International journal of antimicrobial agents</Title>
<ISOAbbreviation>Int J Antimicrob Agents</ISOAbbreviation>
</Journal>
<ArticleTitle>Drug repositioning is an alternative for the treatment of coronavirus COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>105969</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0924-8579(20)30126-6</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijantimicag.2020.105969</ELocationID>
<Abstract><AbstractText>Given the extreme importance of the current pandemic caused by COVID-19, and as scientists agree there is no identified pharmacological treatment, where possible, therapeutic alternatives are raised through drug repositioning. This paper presents a selection of studies involving drugs from different pharmaceutical classes with activity against SARS-CoV-2 and SARS-CoV, with the potential for use in the treatment of COVID-19 disease.</AbstractText>
<CopyrightInformation>Copyright © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serafin</LastName>
<ForeName>Marissa B</ForeName>
<Initials>MB</Initials>
<AffiliationInfo><Affiliation>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bottega</LastName>
<ForeName>Angelita</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Foletto</LastName>
<ForeName>Vitória S</ForeName>
<Initials>VS</Initials>
<AffiliationInfo><Affiliation>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>da Rosa</LastName>
<ForeName>Taciéli F</ForeName>
<Initials>TF</Initials>
<AffiliationInfo><Affiliation>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hörner</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Universidade Federal de Santa Maria, Pós-Graduação Mestrado Profissional em Ciências da Saúde.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hörner</LastName>
<ForeName>Rosmari</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil; Universidade Federal de Santa Maria, Departamento de Análises Clínicas e Toxicológicas, Santa Maria, RS, Brasil. Electronic address: rosmari.ufsm@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Int J Antimicrob Agents</MedlineTA>
<NlmUniqueID>9111860</NlmUniqueID>
<ISSNLinking>0924-8579</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber>
<NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>415SHH325A</RegistryNumber>
<NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>61036-62-2</RegistryNumber>
<NameOfSubstance UI="D017334">Teicoplanin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber>
<NameOfSubstance UI="D000409">Alanine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017334" MajorTopicYN="N">Teicoplanin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Repositioning</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>03</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>6</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32278811</ArticleId>
<ArticleId IdType="pii">S0924-8579(20)30126-6</ArticleId>
<ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105969</ArticleId>
<ArticleId IdType="pmc">PMC7194941</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24841273</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Pharmacol. 2018 Jan;175(2):181-191</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28685814</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Mar 20;:105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 16;43(0):E014</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32061198</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Mar 09;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2018 Feb;150:155-163</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29289665</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2009 Aug;53(8):3416-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19506054</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2011 Nov;92(Pt 11):2542-2548</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21752960</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Braz J Infect Dis. 2018 May - Jun;22(3):252-256</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29963991</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105944</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32179150</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24841269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2011 Oct;7(10):e1002331</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22046132</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15351731</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A01 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001A01 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:32278811
   |texte=   Drug repositioning is an alternative for the treatment of coronavirus COVID-19.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i   -Sk "pubmed:32278811" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Drug repositioning is an alternative for the treatment of coronavirus COVID-19.

Drug repositioning is an alternative for the treatment of coronavirus COVID-19.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Curation

No country items

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki